Obtained her PhD degree in the University of Paris VII in 1993, and trained as a post-doc in Prof. John Dick’s group in Toronto. In 1998, she became Group Leader at the Coriell Institute for Medical Research and Assistant Professor, University of Medicine and Dentistry of New Jersey. In 2001, she joined the London Research Institute. Since 2002, she is also Professor, University College of London and Senior Lecturer at the Institute of Child Health.
Senior Lecturer in Biological Sciences at the University of Huddersfield, since 2015. Previously Junior Research Fellow, College Lecturer In Biochemistry and various postdocs at the University of Oxford (2013-15). Working on DNA replication, genome integrity and transcription factors in human cancers (and also in prokaryotes). Additional interests in phylogenomics and novel protein expression systems.
Principal Investigator of the Transfusion Research Center, Belgian Red Cross Flanders, Belgium. Winner of two PM Mannucci awards of the International Society of Thrombosis and Haemostasis and one Scott Memorial prize of the Biomedical Excellence for Safter Transfusion Collaborative.
Professor of Systems Biology and Genomics at the Harry Perkins Institute of Medical Research at the University of Western Australia, Perth. Studies transcriptional regulatory networks, cell-to-cell communication networks. Was scientific coordinator of the FANTOM5 project while based at RIKEN. Uses next generation sequencing protocols RNA-seq, Cap Analysis of Gene Expression, ChIP-seq etc and bioinformatic approaches to study transcriptional regulation.
Professor of Cellular Immunology (and Head of College of Medical and Dental Sciences Graduate School), University of Birmingham. Raine Visiting Professor, University of Western Australia. CSO & co-Founder, Celentyx Ltd.
Associate Professor of cell biology and Developmental biology in Central University of Rajasthan, India. Received PhD in Human Biology from the Institute for Prevention of Cardiovascular Diseases, Ludwig Maximilian University, Munich, Germany. Awarded “summa cum laude” for Ph.D. work.
Professor of Molecular and Cellular Glycobiology, Department of Biological Science, College of Science, Sungkyunkwan University, Korea,
Co-positional Professor of Department of Medical Device Management and Research,
Samsung Advanced Institute of Health Science and Technology (SAIHST), Former Chairman, Department of Biochemistry and Molecular Biology, COM, DGU. Former Senior Researcher of KRIBB. University of Tokyo MS, PhD. 324 peer reviewed publications. Intl Advisory Bord and Chairs, Intl Symposium on Glycosyltransferases GlycoT2008 and GlycoT2012, Chair of Molecular Eng-2013 TX, USA. Editor, Journal of Glycobiology; eCAM, Current Pharmaceutical Biotechnology and others.
My research group is working to identify genetic mutations that contribute to the development of leukaemia, and studying how these mutations influence a patient’s response to therapy. The cancer landscape is both complex and dynamic and we're using genomic approaches to study how cancer cells evolve in response to treatment.
Associate Member (Professor) in the Department of Pathology and Co-Leader of the Hematologic Malignancies Program at St Jude Children's Research Hospital. Recipient of American Society of Hematology Merit and Scholar Awards, American Association of Cancer Research Team Science Award, American Society of Clinical Investigation (2012)
Vice-Dean Research and Professor of Pharmacology College of Medicine University of Saskatchewan, Saskatoon, Canada. A highly-cited pharmacologist, recipient of Scientist of Canadian Institutes of Health Research, Trinity College Dublin Fellow and Complutense University Madrid Honorary Doctorate awards.
Associate Professor of Biomedical Sciences at Cornell University and Weill Cornell Medical College.
Head Section of Applied Functional Genomics, Department of Translational Oncology, National Center for Tumor Diseases Heidelberg (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany. She trained as a postdoctoral fellow at Brigham and Women’s Hospital and Harvard Medical School in Boston, USA. Research interests include the identification of vulnerabilites in cancer cells that might be exploited for the development of targeted therapies with focus on KRAS mutant cancers and AML.